Here are the episode notes:
UK Bribery Act: what should your company do now, if anything. A continuation of a dialogue from thebriberyact.com.
Lindsey manufacturing and the $297,000 Ferrari.
GlaxoSmithKline’s Lauren Stevens wins one.
Criminal forfeiture, and AML vs. FCPA (and the promised SAR Activity Review)
[...] my colleague Howard Sklar and I recorded Episode 3 in our This Week in the FCPA series, check out our video podcast. One of the items we discussed was the release of BSA Advisory [...]
I would like to hear your comments regarding the ability (or inability) to provide robust representations of data using sampling techniques available in data analytics. I believe you can get a very good picture of what is happening with small, but statistically reliable random samples from a targeted data set. That option is relatively low cost if properly structured and very robust… and proportionate. You can always drill down if you have a questionable finding. If the information system is not that robust, the organization may have problems greater than just compliance. Great series, thanks!
[...] my colleague Howard Sklar and I recorded Episode 3 in our This Week in the FCPA series, check out our video podcast. One of the items we discussed was the release of BSA Advisory [...]